Business

China announces reimbursement drug lists, with six Sanofi medicines included to benefit patients

By Han Jingyan | chinadaily.com.cn

Updated: 2026-11-18 13:34

Share - WeChat
China released the National Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance Drug List (2026) and the Commercial Health Insurance Innovative Drug List (2026) on Nov 14, with six innovative Sanofi medicines and new indications included to benefit more patients. [Photo provided to chinadaily.com.cn]

As China officially released the National Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance Drug List (2026) and the Commercial Health Insurance Innovative Drug List (2026) on Nov 14, six innovative Sanofi medicines and new indications have been included in the two lists.

Dupixent® (dupilumab injection), Myqorzo® (aficamten tablets), Redemplo® (plozasiran sodium injection), Anxu® (rovadicitinib tablets; exclusively licensed worldwide from Chia Tai Tianqing), and Qfitlia® (fitusiran sodium injection) are in the National Reimbursement Drug List, while Cablivi® (caplacizumab for injection) is in the Commercial Health Insurance Innovative Drug List.

"China's healthcare reimbursement policy framework is developing an innovation-support mechanism that spans the entire value chain, from R&D and market access to clinical use and payment," Wayne Shi, president of Sanofi Greater China, said.

Shi added that the six innovative medicines and new indications included in the latest update "will benefit more people in China living with conditions such as asthma, chronic obstructive pulmonary disease, cardiovascular diseases and rare blood disorders".

Sanofi will actively explore diverse pathways to innovation so that more high-quality innovations can benefit patients across China, Shi said.

Sanofi is the only multinational pharmaceutical company with four medicines newly included in the National Reimbursement Drug List, all of which are among the 51 Class 1 innovative drugs added this year.

Dupixent® (dupilumab injection) is the world's first biologic to target IL-4Rα. By inhibiting the IL-4 and IL-13 signaling pathways, it precisely targets type 2 inflammatory diseases. In the latest version of the National Reimbursement Drug List, the reimbursement agreement for Dupixent® for moderate-to-severe atopic dermatitis in children aged six months and older and adults was renewed. Four indications have been included in the reimbursement scope for the first time.

Nearly 100 million people in China are living with chronic obstructive pulmonary disease, with close to 1 million deaths attributable to the disease each year, making it the country's third leading cause of death. In 2024, Dupixent® was approved in China for COPD, ending a decade-long "quiet period" in innovative COPD treatment.

In dermatology, approximately 80 million people in China are living with atopic dermatitis, around 60 percent of whom develop the disease before the age of one.

Myqorzo® (aficamten tablets) is a second-generation cardiac myosin inhibitor. By modulating excessive cardiac contractility, it offers patients a new precision-targeted treatment option. Hypertrophic cardiomyopathy is a serious genetic heart disease that can lead to sudden cardiac death, heart failure, and thromboembolism.

In December 2025, Myqorzo® was first approved in China, ahead of other countries and regions worldwide, including the United States and Europe. It became available to patients in China in March 2026.

Redemplo® (plozasiran sodium injection) is the world's first small interfering RNA medicine targeting APOC3 mRNA. It is currently the only therapy approved in China — in conjunction with dietary control — to reduce triglyceride levels in adults with familial chylomicronemia syndrome. FCS is a rare inherited lipid metabolism disorder. People living with FCS have persistently elevated triglyceride levels and are at risk of recurrent episodes of acute pancreatitis, which in severe cases may lead to multiple organ failure and can even be life-threatening.

As an innovative therapy addressing a longstanding treatment gap in FCS, Redemplo® has received a Breakthrough Therapy designation from both the US Food and Drug Administration and China's National Medical Products Administration. It was approved in China in January 2026.

Anxu® (rovadicitinib tablets) is the world's first JAK/ROCK dual-target inhibitor, representing an innovation originating in China for the treatment of myelofibrosis. Myelofibrosis is a rare, malignant blood disorder that can have an insidious onset, but may be life-threatening. Employing an innovative dual-target mechanism of action, Anxu® was approved in China in February 2026 for first-line treatment. This first-in-class therapy originating in China not only provides patients with a new treatment option, but also opens a new direction for overcoming the limitations of conventional treatment and intervening in the disease process of myelofibrosis.

Qfitlia® (fitusiran sodium injection) is the world's first and only siRNA-based non-factor therapy for hemophilia. By specifically lowering antithrombin levels, it helps rebalance coagulation and expands treatment options for people with hemophilia through a non-factor approach to routine prophylaxis. In December 2025, Qfitlia® became the first innovative hemophilia medicine targeting antithrombin reduction to be approved in China.

Cablivi® (caplacizumab for injection) is the world's first and only innovative nanobody medicine specifically targeting immune-mediated thrombotic thrombocytopenic purpura. By blocking the binding of platelets to von Willebrand factor, it inhibits spontaneous platelet adhesion and prevents the formation of microthrombi. iTTP is an extremely rare and acute, life-threatening condition. In November 2025, Cablivi® was approved in China for use in combination with plasma exchange and immunosuppressive therapy in adults and adolescents aged 12 years and older who weigh at least 40 kilograms. Its approval offers a new treatment option to help patients with this rare, life-threatening condition gain timely disease control and reduce the risk of serious complications.

Copyright 1994 -

Registration Number: 130349

Mobile